Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alecsat
- Development stage
- Phase 2
- Lead developer
- CytoVac
- Modality
- Vaccines & Immunotherapeutics, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ALECSAT is a cell-based immunotherapy developed to treat various cancers, including triple-negative breast cancer, glioblastoma multiforme, hormone-refractory prostate cancer, malignant melanoma, and pancreatic cancer. The therapy utilizes the patient's own immune system by supplementing and strengthening it with tumor-specific cytotoxic lymphocytes (CTLs) and natural killer (NK) cells that are designed to target and destroy tumor cells. ALECSAT is an autologous therapy—meaning it uses the patient’s own cells—which are collected, activated against tumor antigens ex vivo (outside the body), expanded in number, and then reinfused into the patient to enhance anti-tumor immune responses[1][2][3].
- Other names
- ALECSAT
Beyond the preview
Go deeper on alecsat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alecsat.